HomeIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Previous close
$32.99
Day range
$32.71 - $33.66
Year range
$23.95 - $52.34
Market cap
5.34B USD
Avg Volume
1.79M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | 131.61M | 10.14% |
Operating expense | 83.55M | 39.85% |
Net income | -146.94M | -2.90% |
Net profit margin | -111.64 | 6.58% |
Earnings per share | -0.92 | -20.52% |
EBITDA | -144.05M | 1.56% |
Effective tax rate | -0.08% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.15B | -3.00% |
Total assets | 2.81B | 1.77% |
Total liabilities | 2.34B | -5.28% |
Total equity | 475.73M | — |
Shares outstanding | 159.16M | — |
Price to book | 11.03 | — |
Return on assets | -12.62% | — |
Return on capital | -14.71% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -146.94M | -2.90% |
Cash from operations | -150.78M | -0.56% |
Cash from investing | 170.46M | 123.98% |
Cash from financing | 2.20M | -90.67% |
Net change in cash | 22.12M | 143.90% |
Free cash flow | -107.97M | -16.56% |
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Headquarters
Website
Employees
1,069
